Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of Nabriva Therapeutics plc from 31 Dec 2015 to 30 Jun 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Nabriva Therapeutics plc quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD history and change rate from 31 Dec 2015 to 30 Jun 2023.
  • Nabriva Therapeutics plc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending 30 Jun 2023 was $2,255,000, a 89% decline year-over-year.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

Nabriva Therapeutics plc Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2023 $2,255,000 -$17,908,000 -89% 30 Jun 2023 10-Q 19 Oct 2023 2023 Q2
Q1 2023 $1,921,000 -$32,037,000 -94% 31 Mar 2023 10-Q 22 May 2023 2023 Q1
Q4 2022 $12,537,000 -$35,297,000 -74% 31 Dec 2022 10-Q 19 Oct 2023 2023 Q2
Q3 2022 $14,768,000 -$37,406,000 -72% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $20,163,000 -$41,157,000 -67% 30 Jun 2022 10-Q 19 Oct 2023 2023 Q2
Q1 2022 $33,958,000 -$21,060,000 -38% 31 Mar 2022 10-Q 22 May 2023 2023 Q1
Q4 2021 $47,834,000 +$6,244,000 +15% 31 Dec 2021 10-Q 19 Oct 2023 2023 Q2
Q3 2021 $52,174,000 +$10,822,000 +26% 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $61,320,000 +$11,431,000 +23% 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $55,018,000 +$27,636,000 +101% 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $41,590,000 -$44,821,000 -52% 31 Dec 2020 10-K 17 Apr 2023 2022 FY
Q3 2020 $41,352,000 -$36,977,000 -47% 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $49,889,000 -$23,855,000 -32% 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $27,382,000 -$63,660,000 -70% 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $86,411,000 -$15,592,000 -15% 31 Dec 2019 10-K 17 Apr 2023 2022 FY
Q3 2019 $78,329,000 -$22,002,000 -22% 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $73,744,000 -$1,509,000 -2% 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $91,042,000 +$1,601,000 +1.8% 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $102,003,000 +$15,234,000 +18% 31 Dec 2018 10-K 29 Mar 2022 2021 FY
Q3 2018 $100,331,000 -$11,827,000 -11% 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $75,253,000 +$55,164,000 +275% 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $89,441,000 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q4 2017 $86,769,000 +$53,991,000 +165% 31 Dec 2017 10-K 11 Mar 2021 2020 FY
Q3 2017 $112,158,000 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $20,089,000 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q4 2016 $32,778,000 -$3,668,000 -10% 31 Dec 2016 10-K 12 Mar 2020 2019 FY
Q4 2015 $36,446,000 31 Dec 2015 10-K 12 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.